Boehringer's Dulcolax in agency review; Roche rolls back hep C drug prices in India;

> Boehringer Ingelheim's Dulcolax brand kicked off a global creative review, with pitches taking place at the end of June. Report

> Roche ($RHHBY) rolled back the prices on its Exxura treatment for hepatitis C in India, cutting the price by 65% for government institution purchasers. Report

> Bayer and Johnson & Johnson ($JNJ) have presentations on their anticoagulant drug Xarelto scheduled at the International Society on Thrombosis and Haemostasis meeting. Report

> Merck Serono won two prestigious Red Dot Awards for the design of its fertility drug-delivery pens. Release

> Rovi signed up to market Orvatez, a cholesterol-fighting drug that combines Merck & Co.'s ($MRK) Zetia (ezetimibe) with the statin drug atorvastatin, in Spain. Report

And Finally... The biosimilar naming debate is heating up as the FDA plans new guidance by the end of the year. Report

Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.